NICE issues final guidance on NHS use of Bayer's Vitrakvi

27th May 2020 Uncategorised 0

Evidence from trials suggests that tumours with NTRK gene fusions shrink in response to larotrectinib

More: NICE issues final guidance on NHS use of Bayer's Vitrakvi
Source: News